APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hemophilia A Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Hemophilia A Drug Industry Growth and Trends Forecast to 2032

22 December 2025115 pages

Choose your research edition.

Industry ResearchHemophilia A Drug Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemophilia A Drug Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Hemophilia A Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemophilia A Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemophilia A Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Hemophilia A Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Hemophilia A Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Hemophilia A Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hemophilia A Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hemophilia A Drug include Bayer AG, mAbxience SA, LFB SA, Immusoft Corp, Idogen AB, Green Cross Corp, Expression Therapeutics LLC, EpiVax Inc and Dimension Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Hemophilia A Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Hemophilia A Drug market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Hemophilia A Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Hemophilia A Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Hemophilia A Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Hemophilia A Drug Market by Company

Bayer AG

mAbxience SA

LFB SA

Immusoft Corp

Idogen AB

Green Cross Corp

Expression Therapeutics LLC

EpiVax Inc

Dimension Therapeutics Inc

DBV Technologies SA

CSL Ltd

Chugai Pharmaceutical Co Ltd

Catalyst Biosciences Inc

Bioverativ Inc

BioMarin Pharmaceutical Inc

Hemophilia A Drug Segment by Type

ATXF-8117

BAY-1093884

BIVV-001

BS-027125

Concizumab

CSL-689

Others

Hemophilia A Drug Segment by Application

Clinic

Hospital

ASCs

Hemophilia A Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia A Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemophilia A Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia A Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hemophilia A Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Hemophilia A Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of ATXF-8117 Table 2. Major Company of BAY-1093884 Table 3. Major Company of BIVV-001 Table 4. Major Company of BS-027125 Table 5. Major Company of Concizumab Table 6. Major Company of CSL-689 Table 7. Major Company of Others Table 8. Global Hemophilia A Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 9. Global Hemophilia A Drug Sales by Type (2021-2026) & (k units) Table 10. Global Hemophilia A Drug Sales Market Share in Volume by Type (2021-2026) Table 11. Global Hemophilia A Drug Sales by Type (2021-2026) & (US$ Million) Table 12. Global Hemophilia A Drug Sales Market Share in Value by Type (2021-2026) Table 13. Global Hemophilia A Drug Price by Type (2021-2026) & (US$/unit) Table 14. Global Hemophilia A Drug Sales by Type (2027-2032) & (k units) Table 15. Global Hemophilia A Drug Sales Market Share in Volume by Type (2027-2032) Table 16. Global Hemophilia A Drug Sales by Type (2027-2032) & (US$ Million) Table 17. Global Hemophilia A Drug Sales Market Share in Value by Type (2027-2032) Table 18. Global Hemophilia A Drug Price by Type (2027-2032) & (US$/unit) Table 19. North America Hemophilia A Drug Sales by Type (2021-2026) & (k units) Table 20. North America Hemophilia A Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Europe Hemophilia A Drug Sales by Type (2021-2026) & (k units) Table 22. Europe Hemophilia A Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Asia-Pacific Hemophilia A Drug Sales by Type (2021-2026) & (k units) Table 24. Asia-Pacific Hemophilia A Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Latin America Hemophilia A Drug Sales by Type (2021-2026) & (k units) Table 26. Latin America Hemophilia A Drug Sales by Type (2021-2026) & (US$ Million) Table 27. Middle East and Africa Hemophilia A Drug Sales by Type (2021-2026) & (k units) Table 28. Middle East and Africa Hemophilia A Drug Sales by Type (2021-2026) & (US$ Million) Table 29. Hemophilia A Drug Industry Trends Table 30. Hemophilia A Drug Industry Drivers Table 31. Hemophilia A Drug Industry Opportunities and Challenges Table 32. Hemophilia A Drug Industry Restraints Table 33. Global Hemophilia A Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 34. Global Hemophilia A Drug Revenue Market Share by Company (2021-2026) Table 35. Global Hemophilia A Drug Sales by Company (2021-2026) & (k units) Table 36. Global Hemophilia A Drug Sales Share by Company (2021-2026) Table 37. Global Hemophilia A Drug Market Price by Company (2021-2026) & (US$/unit) Table 38. Global Hemophilia A Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 39. Global Hemophilia A Drug Major Company Production Sites and Headquarters Table 40. Global Hemophilia A Drug Company, Product Type & Application Table 41. Global Hemophilia A Drug Company Establishment Date Table 42. Global Company Market Concentration Ratio (CR5 and HHI) Table 43. Global Hemophilia A Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 44. Global Hemophilia A Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 45. Global Hemophilia A Drug Sales by Region (2021-2026) & (k units) Table 46. Global Hemophilia A Drug Sales Market Share in Volume by Region (2021-2026) Table 47. Global Hemophilia A Drug Sales by Region (2021-2026) & (US$ Million) Table 48. Global Hemophilia A Drug Sales Market Share in Value by Region (2021-2026) Table 49. Global Hemophilia A Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 50. Global Hemophilia A Drug Sales by Region (2027-2032) & (k units) Table 51. Global Hemophilia A Drug Sales Market Share in Volume by Region (2027-2032) Table 52. Global Hemophilia A Drug Sales by Region (2027-2032) & (US$ Million) Table 53. Global Hemophilia A Drug Sales Market Share in Value by Region (2027-2032) Table 54. Global Hemophilia A Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 55. Global Hemophilia A Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 56. Global Hemophilia A Drug Sales by Application (2021-2026) & (k units) Table 57. Global Hemophilia A Drug Sales Market Share in Volume by Application (2021-2026) Table 58. Global Hemophilia A Drug Sales by Application (2021-2026) & (US$ Million) Table 59. Global Hemophilia A Drug Sales Market Share in Value by Application (2021-2026) Table 60. Global Hemophilia A Drug Price by Application (2021-2026) & (US$/unit) Table 61. Global Hemophilia A Drug Sales by Application (2027-2032) & (k units) Table 62. Global Hemophilia A Drug Sales Market Share in Volume by Application (2027-2032) Table 63. Global Hemophilia A Drug Sales by Application (2027-2032) & (US$ Million) Table 64. Global Hemophilia A Drug Sales Market Share in Value by Application (2027-2032) Table 65. Global Hemophilia A Drug Price by Application (2027-2032) & (US$/unit) Table 66. North America Hemophilia A Drug Sales by Application (2021-2026) & (k units) Table 67. North America Hemophilia A Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Europe Hemophilia A Drug Sales by Application (2021-2026) & (k units) Table 69. Europe Hemophilia A Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Asia-Pacific Hemophilia A Drug Sales by Application (2021-2026) & (k units) Table 71. Asia-Pacific Hemophilia A Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Latin America Hemophilia A Drug Sales by Application (2021-2026) & (k units) Table 73. Latin America Hemophilia A Drug Sales by Application (2021-2026) & (US$ Million) Table 74. Middle East and Africa Hemophilia A Drug Sales by Application (2021-2026) & (k units) Table 75. Middle East and Africa Hemophilia A Drug Sales by Application (2021-2026) & (US$ Million) Table 76. Bayer AG Company Information Table 77. Bayer AG Business Overview Table 78. Bayer AG Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Bayer AG Hemophilia A Drug Product Portfolio Table 80. Bayer AG Recent Development Table 81. mAbxience SA Company Information Table 82. mAbxience SA Business Overview Table 83. mAbxience SA Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. mAbxience SA Hemophilia A Drug Product Portfolio Table 85. mAbxience SA Recent Development Table 86. LFB SA Company Information Table 87. LFB SA Business Overview Table 88. LFB SA Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. LFB SA Hemophilia A Drug Product Portfolio Table 90. LFB SA Recent Development Table 91. Immusoft Corp Company Information Table 92. Immusoft Corp Business Overview Table 93. Immusoft Corp Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Immusoft Corp Hemophilia A Drug Product Portfolio Table 95. Immusoft Corp Recent Development Table 96. Idogen AB Company Information Table 97. Idogen AB Business Overview Table 98. Idogen AB Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Idogen AB Hemophilia A Drug Product Portfolio Table 100. Idogen AB Recent Development Table 101. Green Cross Corp Company Information Table 102. Green Cross Corp Business Overview Table 103. Green Cross Corp Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Green Cross Corp Hemophilia A Drug Product Portfolio Table 105. Green Cross Corp Recent Development Table 106. Expression Therapeutics LLC Company Information Table 107. Expression Therapeutics LLC Business Overview Table 108. Expression Therapeutics LLC Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Expression Therapeutics LLC Hemophilia A Drug Product Portfolio Table 110. Expression Therapeutics LLC Recent Development Table 111. EpiVax Inc Company Information Table 112. EpiVax Inc Business Overview Table 113. EpiVax Inc Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. EpiVax Inc Hemophilia A Drug Product Portfolio Table 115. EpiVax Inc Recent Development Table 116. Dimension Therapeutics Inc Company Information Table 117. Dimension Therapeutics Inc Business Overview Table 118. Dimension Therapeutics Inc Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Dimension Therapeutics Inc Hemophilia A Drug Product Portfolio Table 120. Dimension Therapeutics Inc Recent Development Table 121. DBV Technologies SA Company Information Table 122. DBV Technologies SA Business Overview Table 123. DBV Technologies SA Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. DBV Technologies SA Hemophilia A Drug Product Portfolio Table 125. DBV Technologies SA Recent Development Table 126. CSL Ltd Company Information Table 127. CSL Ltd Business Overview Table 128. CSL Ltd Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. CSL Ltd Hemophilia A Drug Product Portfolio Table 130. CSL Ltd Recent Development Table 131. Chugai Pharmaceutical Co Ltd Company Information Table 132. Chugai Pharmaceutical Co Ltd Business Overview Table 133. Chugai Pharmaceutical Co Ltd Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. Chugai Pharmaceutical Co Ltd Hemophilia A Drug Product Portfolio Table 135. Chugai Pharmaceutical Co Ltd Recent Development Table 136. Catalyst Biosciences Inc Company Information Table 137. Catalyst Biosciences Inc Business Overview Table 138. Catalyst Biosciences Inc Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 139. Catalyst Biosciences Inc Hemophilia A Drug Product Portfolio Table 140. Catalyst Biosciences Inc Recent Development Table 141. Bioverativ Inc Company Information Table 142. Bioverativ Inc Business Overview Table 143. Bioverativ Inc Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 144. Bioverativ Inc Hemophilia A Drug Product Portfolio Table 145. Bioverativ Inc Recent Development Table 146. BioMarin Pharmaceutical Inc Company Information Table 147. BioMarin Pharmaceutical Inc Business Overview Table 148. BioMarin Pharmaceutical Inc Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 149. BioMarin Pharmaceutical Inc Hemophilia A Drug Product Portfolio Table 150. BioMarin Pharmaceutical Inc Recent Development Table 151. North America Hemophilia A Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 152. North America Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 153. North America Hemophilia A Drug Sales Market Share by Country (2021-2026) Table 154. North America Hemophilia A Drug Sales Forecast by Country (2027-2032) & (k units) Table 155. North America Hemophilia A Drug Sales Market Share Forecast by Country (2027-2032) Table 156. North America Hemophilia A Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. North America Hemophilia A Drug Market Size by Country (2021-2026) & (US$ Million) Table 158. North America Hemophilia A Drug Market Share by Country (2021-2026) Table 159. North America Hemophilia A Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. North America Hemophilia A Drug Market Share Forecast by Country (2027-2032) Table 161. Europe Hemophilia A Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 162. Europe Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 163. Europe Hemophilia A Drug Sales Market Share by Country (2021-2026) Table 164. Europe Hemophilia A Drug Sales Forecast by Country (2027-2032) & (k units) Table 165. Europe Hemophilia A Drug Sales Market Share Forecast by Country (2027-2032) Table 166. Europe Hemophilia A Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Europe Hemophilia A Drug Market Size by Country (2021-2026) & (US$ Million) Table 168. Europe Hemophilia A Drug Market Share by Country (2021-2026) Table 169. Europe Hemophilia A Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Europe Hemophilia A Drug Market Share Forecast by Country (2027-2032) Table 171. Asia-Pacific Hemophilia A Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 172. Asia-Pacific Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 173. Asia-Pacific Hemophilia A Drug Sales Market Share by Country (2021-2026) Table 174. Asia-Pacific Hemophilia A Drug Sales Forecast by Country (2027-2032) & (k units) Table 175. Asia-Pacific Hemophilia A Drug Sales Market Share Forecast by Country (2027-2032) Table 176. Asia-Pacific Hemophilia A Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Asia-Pacific Hemophilia A Drug Market Size by Country (2021-2026) & (US$ Million) Table 178. Asia-Pacific Hemophilia A Drug Market Share by Country (2021-2026) Table 179. Asia-Pacific Hemophilia A Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Asia-Pacific Hemophilia A Drug Market Share Forecast by Country (2027-2032) Table 181. Latin America Hemophilia A Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 182. Latin America Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 183. Latin America Hemophilia A Drug Sales Market Share by Country (2021-2026) Table 184. Latin America Hemophilia A Drug Sales Forecast by Country (2027-2032) & (k units) Table 185. Latin America Hemophilia A Drug Sales Market Share Forecast by Country (2027-2032) Table 186. Latin America Hemophilia A Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. Latin America Hemophilia A Drug Market Size by Country (2021-2026) & (US$ Million) Table 188. Latin America Hemophilia A Drug Market Share by Country (2021-2026) Table 189. Latin America Hemophilia A Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. Latin America Hemophilia A Drug Market Share Forecast by Country (2027-2032) Table 191. Middle East and Africa Hemophilia A Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 192. Middle East and Africa Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 193. Middle East and Africa Hemophilia A Drug Sales Market Share by Country (2021-2026) Table 194. Middle East and Africa Hemophilia A Drug Sales Forecast by Country (2027-2032) & (k units) Table 195. Middle East and Africa Hemophilia A Drug Sales Market Share Forecast by Country (2027-2032) Table 196. Middle East and Africa Hemophilia A Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 197. Middle East and Africa Hemophilia A Drug Market Size by Country (2021-2026) & (US$ Million) Table 198. Middle East and Africa Hemophilia A Drug Market Share by Country (2021-2026) Table 199. Middle East and Africa Hemophilia A Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 200. Middle East and Africa Hemophilia A Drug Market Share Forecast by Country (2027-2032) Table 201. Key Raw Materials Table 202. Raw Materials Key Suppliers Table 203. Hemophilia A Drug Distributors List Table 204. Hemophilia A Drug Customers List Table 205. Research Programs/Design for This Report Table 206. Authors List of This Report Table 207. Secondary Sources Table 208. Primary Sources List of Figures Figure 1. Hemophilia A Drug Image Figure 2. Global Hemophilia A Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hemophilia A Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Hemophilia A Drug Sales (2021-2032) & (k units) Figure 5. ATXF-8117 Image Figure 6. Global ATXF-8117 Sales YoY Growth (2021-2032) & (k units) Figure 7. BAY-1093884 Image Figure 8. Global BAY-1093884 Sales YoY Growth (2021-2032) & (k units) Figure 9. BIVV-001 Image Figure 10. Global BIVV-001 Sales YoY Growth (2021-2032) & (k units) Figure 11. BS-027125 Image Figure 12. Global BS-027125 Sales YoY Growth (2021-2032) & (k units) Figure 13. Concizumab Image Figure 14. Global Concizumab Sales YoY Growth (2021-2032) & (k units) Figure 15. CSL-689 Image Figure 16. Global CSL-689 Sales YoY Growth (2021-2032) & (k units) Figure 17. Others Image Figure 18. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 19. Global Hemophilia A Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 20. Global Hemophilia A Drug Market Share by Type 2025 VS 2032 Figure 21. North America Hemophilia A Drug Sales Market Share in Volume by Type in 2025 Figure 22. North America Hemophilia A Drug Sales Market Share in Value by Type in 2025 Figure 23. Europe Hemophilia A Drug Sales Market Share in Volume by Type in 2025 Figure 24. Europe Hemophilia A Drug Sales Market Share in Value by Type in 2025 Figure 25. Asia-Pacific Hemophilia A Drug Sales Market Share in Volume by Type in 2025 Figure 26. Asia-Pacific Hemophilia A Drug Sales Market Share in Value by Type in 2025 Figure 27. Latin America Hemophilia A Drug Sales Market Share in Volume by Type in 2025 Figure 28. Latin America Hemophilia A Drug Sales Market Share in Value by Type in 2025 Figure 29. Middle East and Africa Hemophilia A Drug Sales Market Share in Volume by Type in 2025 Figure 30. Middle East and Africa Hemophilia A Drug Sales Market Share in Value by Type in 2025 Figure 31. Global Top 5 and 10 Hemophilia A Drug Players Market Share by Revenue in 2025 Figure 32. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Clinic Image Figure 34. Global Clinic Sales YoY Growth (2021-2032) & (k units) Figure 35. Hospital Image Figure 36. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 37. ASCs Image Figure 38. Global ASCs Sales YoY Growth (2021-2032) & (k units) Figure 39. Global Hemophilia A Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global Hemophilia A Drug Market Share by Application 2025 VS 2032 Figure 41. North America Hemophilia A Drug Sales Market Share in Volume by Application in 2025 Figure 42. North America Hemophilia A Drug Sales Market Share in Value by Application in 2025 Figure 43. Europe Hemophilia A Drug Sales Market Share in Volume by Application in 2025 Figure 44. Europe Hemophilia A Drug Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific Hemophilia A Drug Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific Hemophilia A Drug Sales Market Share in Value by Application in 2025 Figure 47. Latin America Hemophilia A Drug Sales Market Share in Volume by Application in 2025 Figure 48. Latin America Hemophilia A Drug Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa Hemophilia A Drug Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa Hemophilia A Drug Sales Market Share in Value by Application in 2025 Figure 51. North America Hemophilia A Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. North America Hemophilia A Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America Hemophilia A Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America Hemophilia A Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Hemophilia A Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Europe Hemophilia A Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Hemophilia A Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe Hemophilia A Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Hemophilia A Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Asia-Pacific Hemophilia A Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Hemophilia A Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific Hemophilia A Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Hemophilia A Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 64. Latin America Hemophilia A Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Hemophilia A Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America Hemophilia A Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Hemophilia A Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 68. Middle East and Africa Hemophilia A Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Hemophilia A Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa Hemophilia A Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Hemophilia A Drug Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. Hemophilia A Drug Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • ATXF-8117
  • BAY-1093884
  • BIVV-001
  • BS-027125
  • Concizumab
  • CSL-689
  • Others
Applications
  • Clinic
  • Hospital
  • ASCs
Companies covered
  • Bayer AG
  • mAbxience SA
  • LFB SA
  • Immusoft Corp
  • Idogen AB
  • Green Cross Corp
  • Expression Therapeutics LLC
  • EpiVax Inc
  • Dimension Therapeutics Inc
  • DBV Technologies SA
  • CSL Ltd
  • Chugai Pharmaceutical Co Ltd
  • Catalyst Biosciences Inc
  • Bioverativ Inc
  • BioMarin Pharmaceutical Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hemophilia A Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Hemophilia A Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Hemophilia A Drug Market by Type
  6. 1.3.1 ATXF-8117
  7. 1.3.2 BAY-1093884
  8. 1.3.3 BIVV-001
  9. 1.3.4 BS-027125
  10. 1.3.5 Concizumab
  11. 1.3.6 CSL-689
  12. 1.3.7 Others
  13. 1.4 Global Hemophilia A Drug Market Size by Type
  14. 1.4.1 Global Hemophilia A Drug Market Size Overview by Type (2021-2032)
  15. 1.4.2 Global Hemophilia A Drug Historic Market Size Review by Type (2021-2026)
  16. 1.4.3 Global Hemophilia A Drug Forecasted Market Size by Type (2027-2032)
  17. 1.5 Key Regions Market Size by Type
  18. 1.5.1 North America Hemophilia A Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.2 Europe Hemophilia A Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.3 Asia-Pacific Hemophilia A Drug Sales Breakdown by Type (2021-2026)
  21. 1.5.4 South America Hemophilia A Drug Sales Breakdown by Type (2021-2026)
  22. 1.5.5 Middle East and Africa Hemophilia A Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Hemophilia A Drug Industry Trends
  2. 2.2 Hemophilia A Drug Industry Drivers
  3. 2.3 Hemophilia A Drug Industry Opportunities and Challenges
  4. 2.4 Hemophilia A Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Hemophilia A Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Hemophilia A Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Hemophilia A Drug Price (2021-2026)
  4. 3.4 Global Hemophilia A Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hemophilia A Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Hemophilia A Drug Company, Product Type & Application
  7. 3.7 Global Hemophilia A Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hemophilia A Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hemophilia A Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hemophilia A Drug Tier 1, Tier 2, and Tier 3
4 Hemophilia A Drug Regional Status and Outlook
  1. 4.1 Global Hemophilia A Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Hemophilia A Drug Historic Market Size by Region
  3. 4.2.1 Global Hemophilia A Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Hemophilia A Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Hemophilia A Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Hemophilia A Drug Forecasted Market Size by Region
  7. 4.3.1 Global Hemophilia A Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Hemophilia A Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Hemophilia A Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Hemophilia A Drug by Application
  1. 5.1 Hemophilia A Drug Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 ASCs
  5. 5.2 Global Hemophilia A Drug Market Size by Application
  6. 5.2.1 Global Hemophilia A Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Hemophilia A Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Hemophilia A Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Hemophilia A Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Hemophilia A Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Hemophilia A Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Hemophilia A Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Hemophilia A Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Bayer AG
  2. 6.1.1 Bayer AG Company Information
  3. 6.1.2 Bayer AG Business Overview
  4. 6.1.3 Bayer AG Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Bayer AG Hemophilia A Drug Product Portfolio
  6. 6.1.5 Bayer AG Recent Developments
  7. 6.2 mAbxience SA
  8. 6.2.1 mAbxience SA Company Information
  9. 6.2.2 mAbxience SA Business Overview
  10. 6.2.3 mAbxience SA Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 mAbxience SA Hemophilia A Drug Product Portfolio
  12. 6.2.5 mAbxience SA Recent Developments
  13. 6.3 LFB SA
  14. 6.3.1 LFB SA Company Information
  15. 6.3.2 LFB SA Business Overview
  16. 6.3.3 LFB SA Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 LFB SA Hemophilia A Drug Product Portfolio
  18. 6.3.5 LFB SA Recent Developments
  19. 6.4 Immusoft Corp
  20. 6.4.1 Immusoft Corp Company Information
  21. 6.4.2 Immusoft Corp Business Overview
  22. 6.4.3 Immusoft Corp Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Immusoft Corp Hemophilia A Drug Product Portfolio
  24. 6.4.5 Immusoft Corp Recent Developments
  25. 6.5 Idogen AB
  26. 6.5.1 Idogen AB Company Information
  27. 6.5.2 Idogen AB Business Overview
  28. 6.5.3 Idogen AB Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Idogen AB Hemophilia A Drug Product Portfolio
  30. 6.5.5 Idogen AB Recent Developments
  31. 6.6 Green Cross Corp
  32. 6.6.1 Green Cross Corp Company Information
  33. 6.6.2 Green Cross Corp Business Overview
  34. 6.6.3 Green Cross Corp Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Green Cross Corp Hemophilia A Drug Product Portfolio
  36. 6.6.5 Green Cross Corp Recent Developments
  37. 6.7 Expression Therapeutics LLC
  38. 6.7.1 Expression Therapeutics LLC Company Information
  39. 6.7.2 Expression Therapeutics LLC Business Overview
  40. 6.7.3 Expression Therapeutics LLC Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Expression Therapeutics LLC Hemophilia A Drug Product Portfolio
  42. 6.7.5 Expression Therapeutics LLC Recent Developments
  43. 6.8 EpiVax Inc
  44. 6.8.1 EpiVax Inc Company Information
  45. 6.8.2 EpiVax Inc Business Overview
  46. 6.8.3 EpiVax Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 EpiVax Inc Hemophilia A Drug Product Portfolio
  48. 6.8.5 EpiVax Inc Recent Developments
  49. 6.9 Dimension Therapeutics Inc
  50. 6.9.1 Dimension Therapeutics Inc Company Information
  51. 6.9.2 Dimension Therapeutics Inc Business Overview
  52. 6.9.3 Dimension Therapeutics Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Dimension Therapeutics Inc Hemophilia A Drug Product Portfolio
  54. 6.9.5 Dimension Therapeutics Inc Recent Developments
  55. 6.10 DBV Technologies SA
  56. 6.10.1 DBV Technologies SA Company Information
  57. 6.10.2 DBV Technologies SA Business Overview
  58. 6.10.3 DBV Technologies SA Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 DBV Technologies SA Hemophilia A Drug Product Portfolio
  60. 6.10.5 DBV Technologies SA Recent Developments
  61. 6.11 CSL Ltd
  62. 6.11.1 CSL Ltd Company Information
  63. 6.11.2 CSL Ltd Business Overview
  64. 6.11.3 CSL Ltd Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 CSL Ltd Hemophilia A Drug Product Portfolio
  66. 6.11.5 CSL Ltd Recent Developments
  67. 6.12 Chugai Pharmaceutical Co Ltd
  68. 6.12.1 Chugai Pharmaceutical Co Ltd Company Information
  69. 6.12.2 Chugai Pharmaceutical Co Ltd Business Overview
  70. 6.12.3 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Product Portfolio
  72. 6.12.5 Chugai Pharmaceutical Co Ltd Recent Developments
  73. 6.13 Catalyst Biosciences Inc
  74. 6.13.1 Catalyst Biosciences Inc Company Information
  75. 6.13.2 Catalyst Biosciences Inc Business Overview
  76. 6.13.3 Catalyst Biosciences Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Catalyst Biosciences Inc Hemophilia A Drug Product Portfolio
  78. 6.13.5 Catalyst Biosciences Inc Recent Developments
  79. 6.14 Bioverativ Inc
  80. 6.14.1 Bioverativ Inc Company Information
  81. 6.14.2 Bioverativ Inc Business Overview
  82. 6.14.3 Bioverativ Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Bioverativ Inc Hemophilia A Drug Product Portfolio
  84. 6.14.5 Bioverativ Inc Recent Developments
  85. 6.15 BioMarin Pharmaceutical Inc
  86. 6.15.1 BioMarin Pharmaceutical Inc Company Information
  87. 6.15.2 BioMarin Pharmaceutical Inc Business Overview
  88. 6.15.3 BioMarin Pharmaceutical Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 BioMarin Pharmaceutical Inc Hemophilia A Drug Product Portfolio
  90. 6.15.5 BioMarin Pharmaceutical Inc Recent Developments
7 North America by Country
  1. 7.1 North America Hemophilia A Drug Sales by Country
  2. 7.1.1 North America Hemophilia A Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Hemophilia A Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Hemophilia A Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Hemophilia A Drug Market Size by Country
  6. 7.2.1 North America Hemophilia A Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Hemophilia A Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Hemophilia A Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Hemophilia A Drug Sales by Country
  2. 8.1.1 Europe Hemophilia A Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Hemophilia A Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Hemophilia A Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Hemophilia A Drug Market Size by Country
  6. 8.2.1 Europe Hemophilia A Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Hemophilia A Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Hemophilia A Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Hemophilia A Drug Sales by Country
  2. 9.1.1 Asia-Pacific Hemophilia A Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Hemophilia A Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Hemophilia A Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Hemophilia A Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Hemophilia A Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Hemophilia A Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Hemophilia A Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Hemophilia A Drug Sales by Country
  2. 10.1.1 South America Hemophilia A Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Hemophilia A Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Hemophilia A Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Hemophilia A Drug Market Size by Country
  6. 10.2.1 South America Hemophilia A Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Hemophilia A Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Hemophilia A Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Hemophilia A Drug Sales by Country
  2. 11.1.1 Middle East and Africa Hemophilia A Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Hemophilia A Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Hemophilia A Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Hemophilia A Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Hemophilia A Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Hemophilia A Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Hemophilia A Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Hemophilia A Drug Value Chain Analysis
  2. 12.1.1 Hemophilia A Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Hemophilia A Drug Production Mode & Process
  7. 12.2 Hemophilia A Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Hemophilia A Drug Distributors
  10. 12.2.3 Hemophilia A Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst